Global Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,160.01 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Anti-Neprilysin Market - Impact of Coronavirus (Covid-19) Pandemic
Cardiac diseases are one of the leading causes of death worldwide so the demand for anti-neprilysin drugs has slightly reduced but this COVID-19 pandemic has not negatively impacted anti-neprilysin market. There is no reduction in the cases of heart failures, as COVID-19 affects the cardiac system in the end stage of COVID-19 infection. The lockdown policies in different countries have resulted in reduction in the supply of anti-neprilysin drugs, which is expected to affect the patients with cardiac conditions. Many patients with cardiac conditions at home are not able to receive prescribed medications due to the shutdown on transportation.
The increasing number of product approvals and launches, adoption of anti-neprilysin drugs, and distribution agreements among key players are the major factors that are expected to drive growth of the anti-neprilysin market during the forecast period.
The rising adoption of anti-neprilysin drugs is expected to boost growth of the anti-neprilysin market during the forecast period. For instance, in June 2016, an analysis published in JAMA Cardiology found that timely and wide adoption of Entresto (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the U.S. alone. This analysis is based on the results of PARADIGM-HF trails on heart failure statistics, is the first to quantify the possible impact of Entresto's potential benefit in reducing death.
Furthermore, the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients, given the expected risk-benefit profile, as it could result in failure to prevent tens of thousands of deaths. These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF if patients in the group defined by the authors were given access to treatment.
The launch of new advanced anti-neprilysin drugs in the market is expected to contribute significantly to the anti-neprilysin market growth. For instance, in January 2016, Novartis International AG announced the launch of Entresto (sacubitril/valsartan) in the U.K. Entresto (sacubitril/valsartan) was approved in Europe in November 2015 to treat patients with heart failure and reduced ejection fraction, a condition where the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body. The drug offers a novel dual mechanism of action to reduce the strain on the failing heart.
Browse 32 Market Data Tables and 34 Figures spread through 168 Pages and in-depth TOC on Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"
To know the latest trends and insights related to global anti-neprilysin market, click the link below:
Several market players are focused on distribution agreements to expand their product portfolio and gain maximum share in the market. For instance, in November 2016, Laboratorios Farmacéuticos Rovi, S.A. announced that it signed an agreement with Novartis Farmacéutica, S.A. (subsidiary of Novartis in Spain) to market Neparvis (sacubitril/valsartan) in Spain, which corresponds to Entresto of Novartis. Under this marketing agreement, ROVI takes the promotion and distribution rights of Neparvis in the Spain, a medicine indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (the proportion of blood leaving the heart).
Key Takeaways of the Anti-Neprilysin Market: